title: The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP.
abstract: Our objective was to evaluate the non-germinal center (GC) profile as a marker for response and survival in DLBCL and to compare the characteristics of patients with GC and non-GC DLBCL treated with rituximab-containing regimens. In this patient-level meta-analysis, retrospective data from 712 newly diagnosed DLBCL patients treated with chemoimmunotherapy from 7 centers were analyzed. GC and non-GC profiles were defined according to the Hans algorithm. Although the non-GC profile showed a trend towards worse overall survival (HR 1.24, 95% CI 0.92-1.66; p=0.15) and progression-free survival (HR 1.29, 95% CI 0.96-1.73; p=0.09), it did not retain its value in the multivariate survival analysis. Additionally, the non-GC profile was independently associated with worse complete response rates (OR 0.55, 95% CI 0.37-0.83; p<0.01) in the multivariate logistic regression analysis. Interestingly, Asian patients had higher proportion of GC DLBCL (p=0.01).
authors.affiliation: Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI 02906, USA. jcastillo@lifespan.org
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
authors.forename: Brady E
authors.initials: BE
authors.lastname: Beltran
authors.forename: Moo-Kon
authors.initials: MK
authors.lastname: Song
authors.forename: Ivana
authors.initials: I
authors.lastname: Ilic
authors.forename: Sirpa
authors.initials: S
authors.lastname: Leppa
authors.forename: Heidi
authors.initials: H
authors.lastname: Nurmi
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Seki
authors.forename: Silvia
authors.initials: S
authors.lastname: Uccella
authors.forename: Jun-Min
authors.initials: JM
authors.lastname: Li
authors.forename: Diana O
authors.initials: DO
authors.lastname: Treaba
authors.forename: Dariusz
authors.initials: D
authors.lastname: Stachurski
authors.forename: James N
authors.initials: JN
authors.lastname: Butera
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000069283:Rituximab; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab